<DOC>
	<DOCNO>NCT01336686</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness MBX-102 compare placebo give orally daily 4 week treatment hyperuricemia patient gout .</brief_summary>
	<brief_title>Safety Efficacy Study MBX-102 Treatment Hyperuricemia Patients With Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Read sign inform consent element consent fully explain question address , prior study procedure . Known gout patient ( per criterion American Rheumatism Association classification acute arthritis primary gout Appendix 3 ) sUA must ≥ 8.0 mg/dL ≤12 mg/dL ULT , patient must agree temporarily discontinue exist ULT sUA must ≥ 8.0 mg/dL ≤12 mg/dL washout Week 1 Male female , 1875 year age Screening Visit All female patient must surgically sterile postmenopausal ( least 45 year age history menses least 2 year ; age history menses least 6 month serum FSH ≥ 40 mIU/mL ) partner undergone vasectomy must agree use two medically accept method contraception include barrier method ( see list Appendix 4 ) entire duration study unless report complete sexual abstinence . Female patient must pregnant lactate Male patient female partner childbearing potential must agree use condom partner must use medically acceptable method contraception entire duration study . Patients must estimate CrCl ≥ 60 mL/min calculate CockcroftGault method Serum creatinine value must ≤ 1.1 mg/dL female ≤ 1.3 mg/dL male Patients must liver function test ≤ 1.5X ULN AST , ALT Tbilirubin , ≤ 2X ULN ALP , ≤ 3X ULN GGT ; ≤ 3X ULN CK All clinical laboratory parameter must within normal limit consider clinically significant participation study Electrocardiogram ( ECG ) must normal , abnormal , consider clinically significant participation study Patients must systolic blood pressure ≤ 160 mm Hg diastolic blood pressure ≤ 90 mm Hg ; know hypertensive patient control medication thiazide diuretic ( BP read ) may include Known suspect secondary hyperuricemia ( e.g . due myeloproliferative disorder , organ transplant ) . Known patient xanthinuria History document suspected kidney stone Over producer uric acid evidence 24hour urinary uric acid &gt; 800 mg ( normal unrestricted diet ) Known infection human immunodeficiency virus ( HIV ) history viral hepatitis type B C History illicit drug alcohol abuse within last 1 year History significant pulmonary disease , upper GI bleeding , document peptic ulcer disease ( unless know H. pylori infection treat successfully without recurrence ) , nephrotic syndrome within last 3 year All patient must stroke , TIA , acute myocardial infarction , congestive heart failure ( NYHA Class IIIV ) , angina pectoris , coronary intervention procedure ( include limit angioplasty , stent placement , coronary revascularization ) , low extremity bypass procedure , systemic intracoronary fibrinolytic therapy within last 5 year Malignancy within last 5 year ( except resect basal cell carcinoma ) Body mass index ( BMI ) &gt; 42 kg/m2 Current expect requirement anticoagulant therapy ( except ≤ 325 mg/day aspirin and/or Plavix® 75 mg/day ) Rheumatoid arthritis autoimmune disease require ongoing treatment Current expect treatment potent CYP3A4 inhibitor ( See Appendix 6 ) , ranolazine , digoxin , cyclosporine , cyclophosphamide cytotoxic agent , sulphonylurea , thiazolidinedione , diuretic , atypical antipsychotic agent , phenytoin Chronic treatment nonsteroidal antiinflammatory drug ( NSAIDs use treat acute flare permit ) Current expect treatment systemic corticosteroid ( except topical , ophthalmic , intraarticular , inhale dose &lt; 1600 μg/day ) treat acute flare Known hypersensitivity colchicine Treatment investigational therapy within 30 day prior Screening Visit , patient receive least one dose blind study drug enrol previous MBX102 trial Any condition compromise ability patient provide inform consent comply objectives procedure protocol , judge investigator and/or medical monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>